BioBridgeXAll companies

Adimab

Contract research organization (CRO) · Lebanon, New Hampshire, United States

Adimab is a contract research organization (CRO) headquartered in Lebanon, New Hampshire, United States. Its earliest recorded incorporation is in 2007. It has reported private securities offerings to the US SEC, most recently $14 million sold in a notice filed in 2012.

adimab.comProfile compiled from public records. Is this your company? Request a correction or update

Adimab at a glance

Typecontract research organization (CRO)
HeadquartersLebanon, New Hampshire, United States
Earliest incorporation on record2007

What does Adimab do?

Private fundraising reported to the SEC

3 Form D notices; the most recent reported $13.8 million sold (2012).

Adimab on the BioBridgeX marketplace

CRO · Assay Development & Screening, Hit-to-Lead, Lead Optimization

Services

Assay Development & ScreeningHit-to-LeadLead OptimizationProtein Sciences & Reagents

Therapeutic areas

OncologyImmunology & InflammationInfectious Disease

Modalities

Monoclonal Antibody (mAb)Bispecific / Multispecific AntibodyProtein / Enzyme (Recombinant)
Compare quotes

Unclaimed listing. Claim this profile

Frequently asked questions about Adimab

Where is Adimab headquartered?

Adimab is headquartered in Lebanon, New Hampshire, United States.

What does Adimab do?

Adimab is a contract research organization (CRO).

When was Adimab founded?

The earliest incorporation on record for Adimab is in 2007, according to public company registers.

Similar companies

Sources

Location data: GeoNames (geonames.org), CC BY 4.0.

Last updated 2026-09-23.